Conmed Corp Stock Price, News & Analysis

CONMED (NYSE: CNMD) has announced it will release its fourth quarter 2024 financial results after market close on Wednesday, February 5, 2025. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results. Interested parties can pre-register for the telephone conference, and a webcast will be available through the Investors section of CONMED's website. A replay of the webcast will be accessible approximately one hour after the call concludes.

CONMED (NYSE: CNMD) has announced its upcoming participation in the J.P. Morgan Healthcare Conference. The company's leadership, including President and CEO Patrick J. Beyer and Executive Vice President and CFO Todd W. Garner, will deliver a presentation on Monday, January 13, 2025, at 4:30 p.m. PT (7:30 p.m. ET) in San Francisco, CA.

Investors and interested parties can access a live audio webcast of the presentation through the "Investors" section on CONMED's website at www.conmed.com. The presentation will also be available for replay after the event.

CONMED (NYSE: CNMD) has announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share. The dividend will be paid on January 3, 2025, to shareholders of record as of December 20, 2024. The dividend declaration was made on December 9, 2024.

CONMED (NYSE: CNMD) announced its leadership team's upcoming participation in a fireside chat at the Piper Sandler Healthcare Conference. President and CEO Curt R. Hartman, EVP and CFO Todd W. Garner, and COO Pat J. Beyer will represent the company at the event scheduled for December 3, 2024, at 12:30 p.m. ET. The session will be accessible via live video webcast through CONMED's website investor section and will remain available for replay after the event.

CONMED (NYSE: CNMD) has announced its participation in two upcoming investor conferences in November 2024. The company will participate in fireside chats at the Stifel Healthcare Conference in New York on November 19 at 8:35 a.m. ET, featuring President and CEO Curt R. Hartman and VP of U.S. Orthopedics Nate Miersma. The second presentation will be at the Jefferies London Healthcare Conference on November 20 at 11:00 a.m. GMT, featuring EVP and CFO Todd W. Garner and COO Pat J. Beyer. Both sessions will be available via webcast through CONMED's website investor section.

CONMED (NYSE: CNMD) announced its third-quarter 2024 financial results. Sales reached $316.7 million, marking a 4.0% year-over-year increase as reported and 4.3% in constant currency. Diluted net earnings per share (GAAP) were $1.57, compared to $0.50 in the third quarter of 2023. Adjusted diluted net earnings per share rose by 16.7% to $1.05. The company announced that COO Patrick Beyer will succeed Curt Hartman as President and CEO effective January 1, 2025. The updated full-year revenue guidance is now $1.300 billion to $1.305 billion, slightly down from the prior range of $1.305 billion to $1.315 billion. Full-year adjusted diluted net earnings per share are expected to be in the range of $4.00 to $4.05, up from the prior range of $3.95 to $4.02. Foreign currency impact is expected to be immaterial on both revenue and earnings per share for the full year.

CONMED (NYSE: CNMD) announced a leadership transition as CEO Curt R. Hartman will retire effective January 1, 2025. Current COO Patrick Beyer will succeed as President and CEO. During Hartman's 10-year tenure, CONMED nearly doubled revenues and more than doubled profitability through portfolio expansion and strategic acquisitions. Martha Goldberg Aronson will become Board Chair on October 31, 2024. Hartman will continue as a Director through December 2024 and remain as an advisor until March 2027. Beyer, who joined CONMED in 2014, has served in various leadership roles including President of International and Global Orthopedics, leading key acquisitions like In2Bones and BioRez.

CONMED (NYSE: CNMD) has released preliminary financial information for the third quarter of 2024. The company anticipates revenue between $315 million and $318 million, with adjusted diluted net earnings per share growth exceeding the previously guided 9% to 11%. CONMED will disclose full financial results on October 30, 2024, after market close, followed by a conference call at 4:30 p.m. ET.

The company emphasizes that this information is preliminary and subject to completion. While prepared in good faith and consistent with prior periods, actual results may differ materially as financial closing procedures for the period ended September 30, 2024, have not been completed. Investors are cautioned against relying heavily on this preliminary data.

CONMED (NYSE: CNMD) has announced its participation in a virtual fireside chat at the CL King 22nd Annual Best Ideas Conference. The event is scheduled for September 16, 2024, at 10:15 a.m. ET. Representing CONMED will be Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive Vice President and CFO.

Investors and interested parties can access a live video webcast of the fireside chat through the 'Investors' section of CONMED's official website at www.conmed.com. The webcast will also be available for replay after the event concludes, providing an opportunity for those unable to attend live to catch up on the discussion.